Georgiamune

Executive Summary

Georgiamune is a private, pre-clinical biotechnology company headquartered in Atlanta, GA, founded in 2019 with a mission to reprogram immune responses for the treatment of cancer and autoimmune diseases. The company is developing first-in-class therapeutics, including dual-functioning antibodies and small molecules, designed to regulate signaling pathways and restore immune homeostasis. By targeting both immune activation in oncology and immune suppression in autoimmunity, Georgiamune aims to address significant unmet medical needs across two large therapeutic areas. As a pre-clinical entity, Georgiamune's progress is at an early stage, with its lead programs still in discovery and IND-enabling studies. The company's platform has the potential to generate new mechanisms of action, but validation through preclinical data and regulatory filings is needed. Key near-term catalysts include the filing of an IND for its lead dual-function antibody candidate, expected in the second half of 2026, and the presentation of preclinical proof-of-concept data that could highlight the platform's versatility. A strategic partnership or licensing deal could also serve as a value inflection point, providing external validation and funding. However, the early-stage nature of the pipeline and lack of public disclosures contribute to a moderate conviction.

Upcoming Catalysts (preview)

• H2 2026IND filing for lead dual-function antibody candidate60% success
• Q3 2026Preclinical proof-of-concept data presentation70% success
• 2026Strategic partnership or licensing deal50% success